Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS ravulizumab for prevention of major adverse kidney events after cardiac surgery in chronic kidney disease
MOH_2023-05-14_012632Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing Ultomiris with Placebo (2 arms). Primary endpoint: Major adverse kidney events at day 90. Started May 2023; status: recruiting.
02
Drugs
ravulizumab
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on MOH_2023-05-14_012632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-05-14_012632.